Shanghai Fosun Pharmaceutical (02196) released its annual performance, with a net profit attributable to the parent company of 3.371 billion yuan, an increase of 21.69% year-on-year.

Shanghai Fosun Pharmaceutical (02196) released its annual results for the year ending December 31, 2025. The group achieved operating revenue of RMB 41.662 billion, an increase of 1.45% year-on-year; net profit attributable to shareholders of the listed company was RMB 3.371 billion, an increase of 21.69% year-on-year; basic earnings per share were RMB 1.27, with a proposed cash dividend of RMB 3.90 per 10 shares (pre-tax). During the reporting period, the group's net cash flow from operating activities was RMB 5.213 billion, an increase of 16.45% year-on-year. This performance was achieved under various pressures such as normalized group procurement and the long R&D innovation cycle with high investment. The group is currently in a critical stage of transitioning to a global innovative pharmaceutical and health group. During the reporting period, the proportion of revenue from innovative drugs in the pharmaceutical business revenue and the proportion of revenue from overseas business in operating revenue both increased to over 30%, further solidifying the underlying logic of high-quality development. The steady growth of the group's performance during the reporting period was not derived from the short-term outbreak of a single product, but the deep coupling and resonation of the two strategic engines of R&D innovation and globalized operations. In terms of innovation leadership, the group has always adhered to the integrated "research-produce-sell" closed-loop thinking, with R&D investment precisely targeting unmet clinical needs. In 2025, the group's total R&D investment reached RMB 5.913 billion, with the proportion of R&D investment in innovative drugs reaching 72.77%. High-intensity, high-focus investment directly translated into fruitful results: during the reporting period, two independently developed potential BIC (Best-in-class) small molecule innovative drugs, Fomatinib (lupuslovatinib tablets) and Fothinib (vilivislib capsules), were approved for marketing in China and quickly included in the 2025 national medical insurance catalog, achieving efficient conversion from clinical value to commercial value. Sorelizumab injection (anti-PD-1 monoclonal antibody) not only continued to increase in multiple domestic treatments for lung and gastric cancer but also successfully obtained approval from the European Commission, becoming the first anti-PD-1 monoclonal antibody approved for extensive stage small cell lung cancer in the EU. As of the date of this report, this drug has been approved in over 40 countries and regions worldwide, truly reflecting Chinese wisdom and global value. It is worth mentioning that the group's innovation has shifted from catching up to running side by side, and even starting to lead in certain areas.